Acquired cystic kidney disease (ACKD) Treatment Drugs Market Analysis By Treatment Type (Antibiotics, Non Steroidal Anti inflammatory drugs, Others); Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Others) & Forecast
- PUBLISHED ON
- 2024-10-03
- NO OF PAGES
- 279
- CATEGORY
- Healthcare & Life Sciences
Acquired cystic kidney disease (ACKD) is a condition in which cysts form in the kidneys of people who have chronic kidney disease (CKD). The disease typically develops after a person has been on dialysis for an extended period, and the prevalence of ACKD increases with the duration of dialysis. Treatment options for ACKD are limited, and no cure currently exists.
There are no drugs specifically approved for the treatment of ACKD. However, some drugs have shown promise in treating the symptoms associated with the disease. For example, pain medications such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be used to manage pain caused by the cysts. In addition, drugs that lower blood pressure, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), may be used to slow the progression of CKD and reduce the risk of cardiovascular disease.
Several companies are currently developing drugs that may have potential in treating ACKD. These drugs target various pathways and mechanisms involved in the development and progression of the disease. For example, several companies are developing drugs that target the mTOR pathway, which plays a role in cyst formation. Other companies are developing drugs that target the Wnt/β-catenin signaling pathway, which is also involved in cyst formation.
The ACKD treatment drugs market is currently in its early stages, and there are no drugs specifically approved for the treatment of the disease. However, the market is expected to grow as more drugs enter clinical development and as the prevalence of CKD and ACKD continues to rise. The market is also expected to be driven by the increasing focus on personalized medicine and the development of targeted therapies for specific patient populations.
Report Scope
Report Attributes | Description |
Market Size in 2022 | USD 1.78 Billion |
Market Forecast in 2032 | USD 4.34 Billion |
CAGR % 2023-2031 | 5.6% |
Base Year | 2022 |
Historic Data | 2019-2021 |
Forecast Period | 2023-2031 |
Report USP | Production, Consumption, company share, company heatmap, company production capacity, growth factors and more |
Segments Covered | By Treatment Type, By Distribution Channel |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Abbott Laboratories, Hoffmann- La Roche Ltd, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Corden Pharma International, Pfizer Limited, Sanofi, Merck and Co. Inc., Allergan, Baxter International |
Segment Overview
Acquired cystic kidney disease (ACKD) is a condition in which noncancerous cysts develop in the kidneys of individuals with chronic kidney disease (CKD). Treatment for ACKD typically involves managing the underlying CKD and addressing any complications that may arise from the cysts. There are currently no drugs specifically approved for the treatment of ACKD.
However, there are drugs used to manage CKD and its associated complications that may also be used to treat ACKD.
1. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - these drugs are used to treat high blood pressure and proteinuria in CKD patients, and may also help slow the progression of CKD. They may also be used to manage complications of ACKD, such as hypertension.
2. Diuretics - these drugs help remove excess fluid from the body, and may be used to manage fluid retention in CKD patients with ACKD.
3. Phosphate binders - these drugs are used to control high phosphate levels in CKD patients, which can lead to bone problems. They may also be used to manage complications of ACKD, such as hyperphosphatemia.
4. Erythropoietin-stimulating agents (ESAs) - these drugs stimulate the production of red blood cells and may be used to treat anaemia in CKD patients, including those with ACKD.
5. Statins - these drugs are used to lower cholesterol levels in CKD patients, and may also help reduce the risk of cardiovascular disease in individuals with ACKD.
It is important to note that the use of these drugs for ACKD treatment is off-label, meaning that they have not been specifically approved by regulatory agencies for this purpose. Treatment decisions should be made on an individual basis, taking into account the patient's medical history and current condition.
Geographical Overview
Acquired cystic kidney disease (ACKD) is a rare condition characterized by the development of fluid-filled sacs called cysts in the kidneys, usually in people who have chronic kidney disease (CKD). There is currently no cure for ACKD, and treatment focuses on managing its symptoms and complications.
There are no specific drugs that have been developed to treat ACKD, but there are several medications that can be used to manage its symptoms and complications. These include:
1. Pain relievers: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen may be used to relieve pain caused by cysts.
2. Blood pressure medications: ACE inhibitors or angiotensin receptor blockers (ARBs) may be prescribed to control high blood pressure, which can worsen ACKD.
3. Antibiotics: If an infected cyst is present, antibiotics may be prescribed to treat the infection.
4. Iron supplements: People with ACKD may be at increased risk of anemia due to blood loss in urine or decreased production of erythropoietin by the kidneys. Iron supplements may be prescribed to treat anemia.
5. Erythropoietin stimulating agents: If anemia is severe, erythropoietin stimulating agents (ESAs) may be used to increase red blood cell production.
The market for these drugs is global, as ACKD affects people worldwide. However, the availability and accessibility of these drugs may vary by region, as healthcare systems and regulations differ between countries.
COVID Impact
The COVID-19 pandemic has had a significant impact on the global healthcare industry, including the market for drugs used in the treatment of acquired cystic kidney disease. Acquired cystic kidney disease (ACKD) is a condition that can occur in patients with chronic kidney disease who have been on dialysis for an extended period. This condition can lead to the formation of cysts in the kidneys, which can cause various complications.
The impact of the pandemic on the ACKD treatment drugs market has been mixed. On the one hand, the increased demand for healthcare services due to the pandemic has led to a greater focus on chronic conditions such as kidney disease, which has driven demand for ACKD treatment drugs. On the other hand, disruptions to supply chains and manufacturing processes have resulted in shortages of some drugs, which has affected the availability of ACKD treatments.
Some of the key drugs used in the treatment of ACKD include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and statins. These drugs are used to control blood pressure, reduce inflammation, and manage other symptoms of ACKD. During the pandemic, the demand for these drugs has remained relatively stable, although there have been some shortages due to disruptions in the supply chain.
Overall, the impact of the COVID-19 pandemic on the ACKD treatment drugs market has been relatively modest compared to other areas of healthcare. However, the ongoing nature of the pandemic and the potential for future waves of infections mean that the situation remains fluid, and it is important for healthcare providers and drug manufacturers to remain vigilant and responsive to changes in demand and supply.
Competitive Analysis
The acquired cystic kidney disease (ACKD) is a rare condition that is characterized by the development of cysts in the kidneys due to long-term kidney disease, such as chronic kidney disease or end-stage renal disease. The treatment of ACKD is focused on managing symptoms and preventing complications, such as infection or bleeding. While there are currently no specific drugs approved for the treatment of ACKD, several medications may be used to manage symptoms and prevent complications.
One of the main drugs used to manage ACKD is antibiotics. Antibiotics are used to prevent and treat infections that may develop as a result of the cysts in the kidneys. Common antibiotics used to treat ACKD include ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole.
Another class of drugs that may be used to manage ACKD are non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are used to manage pain and inflammation that may be associated with the cysts in the kidneys. Examples of NSAIDs that may be used to manage ACKD include ibuprofen and naproxen.
In addition to antibiotics and NSAIDs, other medications may be used to manage specific symptoms or complications associated with ACKD. For example, antihypertensive medications may be used to manage high blood pressure, which is a common complication of ACKD. Examples of antihypertensive medications that may be used to manage ACKD include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
Overall, the market for drugs used to manage ACKD is relatively small due to the rarity of the condition. However, there is ongoing research aimed at developing more targeted therapies for the treatment of ACKD. As such, it is important for pharmaceutical companies to stay up-to-date on the latest developments in the field in order to remain competitive and capitalize on emerging opportunities.
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $3499
Only Three Thousand Four Hundred Ninety Nine US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4499
Only Four Thousand Four Hundred Ninety Nine US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5499
Only Five Thousand Four Hundred Ninety Nine US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI